With new PhI­II da­ta in hand, Der­ma­vant lines up top­i­cal pso­ri­a­sis con­tender for a sprint to the fin­ish line

With new PhI­II da­ta in hand, Der­ma­vant lines up top­i­cal pso­ri­a­sis con­tender for a sprint to the fin­ish line

Source: 
Endpoints
snippet: 

In the next couple months, Dermavant CEO Todd Zavodnick says he’ll sprint to the FDA with tapinarof, the company’s “cosmetically elegant” vanishing cream to treat psoriasis. But before that, he has more Phase III data to share.